Perceptive Advisors’s Traws Pharma TRAW Stock Holding History

Perceptive Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-421,781	Closed	-$970K	–	104
2025 Q1	$970K	Buy	421,781 +257,624	+157%	+$1.34M	0.03%	78
2024 Q4	$1.46M	Buy	+164,157	New	+$914K	0.04%	88

Other funds holding TRAW

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors's TRAW Position: Q2 2025 in Review

Perceptive Advisors sold out of Traws Pharma (TRAW) in Q2 2025, closing a stake of 421,781 shares — an estimated $970K sold.

Perceptive Advisors first reported a position in TRAW in Q4 2024 and held it in 2 quarters. The position peaked at $1.46M in Q4 2024. 19 funds tracked by Wall St. Rank hold TRAW as of Q2 2025.

Perceptive Advisors reported no remaining Traws Pharma position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 421,781 Traws Pharma shares in Q2 2025, an estimated $970K.
Perceptive Advisors first reported a position in Traws Pharma in Q4 2024 and held it in 2 quarters.
Perceptive Advisors's Traws Pharma position peaked at $1.46M in Q4 2024.
19 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.